Mixed lineage rearranged leukaemia: Pathogenesis and targeting DOT1L

Current Opinion in Hematology

Volumn 22, Issue 2, 2015, Pages 92-96

  Stein, Eytan M ^a   Tallman, Martin S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

DOT1L; EPZ 5676; mixed lineage leukaemia

Indexed keywords

1 [3 [[5 (4 AMINO 5 BROMO 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL) 3,4 DIHYDROXYTETRAHYDRO 2 FURFURYL](ISOPROPYL)AMINO]PROPYL] 3 (4 TERT BUTYLPHENYL)UREA; 2 (6 AMINO 9H PURIN 9 YL) 5 [[[3 [2 (5 TERT BUTYL 1H BENZIMIDAZOL 2 YL)ETHYL]CYCLOBUTYL](ISOPROPYL)AMINO]METHYL]TETRAHYDROFURAN 3,4 DIOL; HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE DOT1L; MIXED LINEAGE LEUKEMIA PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DOT1L PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; METHYLTRANSFERASE; MLL PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHROMOSOME 11Q; DRUG TARGETING; GENE LOCUS; GENE TRANSLOCATION; GRANULOCYTIC SARCOMA; HISTONE METHYLATION; HUMAN; LEUKEMIA; LEUKEMIA REMISSION; LEUKEMOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG SCREENING; GENETICS; LEUKEMIA, BIPHENOTYPIC, ACUTE; METABOLISM; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LEUKEMIA, BIPHENOTYPIC, ACUTE; METHYLTRANSFERASES; MOLECULAR TARGETED THERAPY; MYELOID-LYMPHOID LEUKEMIA PROTEIN; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84923254803     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000123     Document Type: Review

References (20)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33:451-458.
2. Ziemin-van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A 1991; 88:10735-10739.
3. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100:4325-4336.
4. Schoch C, Schnittger S, Kern W, et al. Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia. Haematologica 2003; 88:351-352.
5. Shih LY, Liang DC, Fu JF, et al. Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia 2006; 20:218-223.
6. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116:354-365.
7. Garrido SM, Bryant E, Appelbaum FR. Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11q23 abnormalities. Leuk Res 2000; 24:481-486.
8. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 1999; 93:3983-3993.
9. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109:3189-3197.
10. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000; 96:24-33.
11. Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117:2137-2145.
12. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71:691-700.
13. Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyl-transferase activity to Hox gene promoters. Mol Cell 2002; 10:1107-1117.
14. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005; 121:167-178.
15. Mueller D, Bach C, Zeisig D, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007; 110:4445-4454.
16. Bernt KM, Zhu N, Sinha AU, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011; 20:66-78.
17. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20:53-65.
18. Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013; 122:1017-1025.
19. Yu W, Chory EJ, Wernimont AK, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012; 3:1288.
20. Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor EPZ-5676: safety and activity in relapsed/refractory patients with MLL-rearranged leukemia. ASH annual meeting 2014, Oral Abstract Program Blood 2014; 124:387.